AG
INMB icon

Advisor Group’s INmune Bio INMB Stock Holding History

Advisor Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
200
– – ﹤0.01% 5147
2019
Q3 		$1K Hold
200
– – ﹤0.01% 5123
2019
Q2 		$2K Buy
+200
New +$2.02K ﹤0.01% 4973

Other funds holding INMB

FAIM
Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CCM
Covington Capital Management Los Angeles, California $2.32B AUM 12.18% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Advisor Group's INMB Position: Q4 2019 in Review

Advisor Group held its INmune Bio (INMB) position steady in Q4 2019 at 200 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5147.

Advisor Group first reported a position in INMB in Q2 2019 and has held it in 3 quarters since. The position peaked at $2K in Q2 2019. 11 funds tracked by Wall St. Rank hold INMB as of Q4 2019.

  • Advisor Group held 200 shares of INmune Bio worth $1K as of Q4 2019.
  • Advisor Group left its INmune Bio share count unchanged in Q4 2019.
  • INmune Bio made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5147 holding.
  • Advisor Group first reported a position in INmune Bio in Q2 2019 and has held it in 3 quarters since.
  • Advisor Group's INmune Bio position peaked at $2K in Q2 2019.
  • 11 funds tracked by Wall St. Rank held INmune Bio as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.